CMET as a potential therapeutic target in gastric cancer (Review)

International Journal of Molecular Medicine

Volumn 32, Issue 6, 2013, Pages 1247-1254

  Teng, Lisong ^a   Lu, Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

CMET; CMET inhibitors; Drug resistance; Gastric cancer; Targeted therapy

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

CANCER THERAPY; DRUG RESISTANCE; DRUG TARGETING; ENVIRONMENT; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84892146505     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1531     Document Type: Review

References (88)

1. Garcia M, Jemal A, Ward EM, et al: Global Cancer Facts and Figures 2007. GA: American Cancer Society, Atlanta, 2007.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Verdecchia A, Santaquilani M and Sant M: Survival for cancer patients in Europe. Ann Ist Super Sanita 45: 315-324, 2009.
4. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
5. Deng N, Goh LK, Wang H, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673-684, 2012.
6. Bussolino F, Di Renzo MF, Ziche M, et al: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641, 1992.
7. Zhang YW, Su Y, Volpert OV and Vande Woude GF: Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100: 12718-12723, 2003.
8. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S and Vande Woude GF: The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 95: 14417-14422, 1998.
9. Webb CP, Taylor GA, Jeffers M, et al: Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 17: 2019-2025, 1998.
10. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103, 2012.
11. Nakajima M, Sawada H, Yamada Y, et al: The prognostic significance of amplification and overexpression of cMET and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902, 1999.
12. Lee J, Seo JW, Jun HJ, et al: Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25: 1517-1524, 2011.
13. Tang Z, Zhao M, Ji J, et al: Overexpression of gastrin and cMET protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep 11: 333-339, 2004.
14. Chen CT, Kim H, Liska D, Gao S, Christensen JG and Weiser MR: MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 11: 660-669, 2012.
15. Kneissl J, Keller S, Lorber T, et al: Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int J Oncol 41: 733-744, 2012.
16. Oliner KD, Tang R, Anderson A, et al: Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. Proc ASCO abs. 4005, 2012.
17. Catenacci DV, Henderson L, Xiao SY, et al: Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 1: 573-579, 2011.
18. Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33, 1984.
19. Park M, Dean M, Cooper CS, et al: Mechanism of met oncogene activation. Cell 45: 895-904, 1986.
20. Park M, Dean M, Kaul K, Braun MJ, Gonda MA and Vande Woude G: Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci USA 84: 6379-6383, 1987.
21. Bottaro DP, Rubin JS, Faletto DL, et al: Identification of the hepatocyte growth factor receptor as the cMET proto-oncogene product. Science 251: 802-804, 1991.
22. Nakamura T, Nishizawa T, Hagiya M, et al: Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443, 1989.
23. Stoker M, Gherardi E, Perryman M and Gray J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327: 239-242, 1987.
24. Peschard P and Park M: From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26: 1276-1285, 2007.
25. Ponzetto C, Bardelli A, Zhen Z, et al: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261-271, 1994.
26. Nguyen L, Holgado-Madruga M, Maroun C, et al: Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J Biol Chem 272: 20811-20819, 1997.
27. Mughal A, Aslam HM, Khan AM, Saleem S, Umah R and Saleem M: Bcr-Abl tyrosine kinase inhibitors-current status. Infect Agent Cancer 8: 23, 2013.
28. Peters S and Adjei AA: MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9: 314-326, 2012.
29. Yamamoto N, Mammadova G, Song RX, Fukami Y and Sato K: Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci 119: 4623-4633, 2006.
30. Khoury H, Naujokas MA, Zuo D, et al: HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell 16: 550-561, 2005.
31. Bauer TW, Somcio RJ, Fan F, et al: Regulatory role of cMET in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 5: 1676-1682, 2006.
32. Uehara Y, Minowa O, Mori C, et al: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702-705, 1995.
33. Woolf AS, Kolatsi-Joannou M, Hardman P, et al: Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J Cell Biol 128: 171-184, 1995.
34. Bladt F, Riethmacher D, Isenmann S, Aguzzi A and Birchmeier C: Essential role for the cMET receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768-771, 1995.
35. Zhang YW and Vande Woude GF: HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88: 408-417, 2003.
36. Chmielowiec J, Borowiak M, Morkel M, et al: cMET is essential for wound healing in the skin. J Cell Biol 177: 151-162, 2007.
37. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS and Comoglio PM: Tyrosine kinase receptor indistinguishable from the cMET protein. Nature 339: 155-156, 1989.
38. Soman NR, Correa P, Ruiz BA and Wogan GN: The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA 88: 4892-4896, 1991.
39. Yu J, Miehlke S, Ebert MP, et al: Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer 88: 1801-1806, 2000.
40. Lee HE, Kim MA, Lee HS, et al: MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107: 325-333, 2012.
41. Janjigian YY, Tang LH, Coit DG, et al: MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20: 1021-1027, 2011.
42. Retterspitz MF, Monig SP, Schreckenberg S, et al: Expression of {beta}-catenin, MUC1 and cMET in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res 30: 4635-4641, 2010.
43. Park WS, Oh RR, Kim YS, et al: Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. APMIS 108: 195-200, 2000.
44. Tsugawa K, Yonemura Y, Hirono Y, et al: Amplification of the cMET, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55: 475-481, 1998.
45. Graziano F, Galluccio N, Lorenzini P, et al: Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29: 4789-4795, 2011.
46. Shi J, Yao D, Liu W, et al: Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 13: 4714-4726, 2012.
47. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68-73, 1997.
48. Olivero M, Valente G, Bardelli A, et al: Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82: 640-643, 1999.
49. Lee JH, Han SU, Cho H, et al: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19: 4947-4953, 2000.
50. Asaoka Y, Tada M, Ikenoue T, et al: Gastric cancer cell line Hs746T harbors a splice site mutation of cMET causing juxtamembrane domain deletion. Biochem Biophys Res Commun 394: 1042-1046, 2010.
51. Burgess T, Coxon A, Meyer S, et al: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/cMET-dependent human tumors. Cancer Res 66: 1721-1729, 2006.
52. Jun HT, Sun J, Rex K, et al: AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 13: 6735-6742, 2007.
53. Gordon MS, Sweeney CS, Mendelson DS, et al: Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 16: 699-710, 2010.
54. Iveson T, Donehower RC, Davidenko I, et al: 6504 ORAL safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma. Eur J Cancer 47: S443, 2011.
55. First-line treatment for locally advanced or metastatic mesenchymal epithelial transition factor (MET)-positive gastric, lower esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (RILOMET-1). http://www. clinicaltrials.gov/ct2/show/NCT01697072. Accessed May 17, 2013.
56. MEGA (Met or EGFR inhibition in gastroesophageal adenocarcinoma): FOLFOX alone or in combination with AMG 102 or Panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma. http://www. clinicaltrials.gov/ct2/show/NCT01443065. Accessed May 17, 2013.
57. Martens T, Schmidt NO, Eckerich C, et al: A novel one-armed anti-cMET antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12: 6144-6152, 2006.
58. Penuel E, Li C, Parab V, et al: HGF as a Circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther 12: 1122-1130, 2013.
59. Jagoda EM, Lang L, Bhadrasetty V, et al: Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med 53: 1592-1600, 2012.
60. A study of Onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative gastroesophageal cancer. http://clinicaltrials. gov/ct2/show/NCT01590719. Accessed May 15, 2013.
61. A study of Onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and Met-positive gastroesophageal cancer (MetGastric). http://www.clinicaltrials.gov/ct2/show/NCT01662869. Accessed May 15, 2013.
62. Munshi N, Jeay S, Li Y, et al: ARQ 197, a novel and selective inhibitor of the human cMET receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9: 1544-1553, 2010.
63. Katayama R, Aoyama A, Yamori T, et al: Cytotoxic activity of tivantinib (ARQ 197) is not due solely to cMET inhibition. Cancer Res 73: 3087-3096, 2013.
64. Muro K, Ryu M-H, Yasui H, et al: A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. Proc ASCO abs.x 4082, 2012.
65. Phase I/II trial of Tivantinib with FOLFOX for the treatment of advanced solid tumors and previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal junction or stomach. http://www.clinicaltrials.gov/ ct2/show/NCT01611857. Accessed May 15, 2013.
66. Okamoto W, Okamoto I, Arao T, et al: Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 11: 1557-1564, 2012.
67. Lennerz JK, Kwak EL, Ackerman A, et al: MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29: 4803-4810, 2011.
68. Qian F, Engst S, Yamaguchi K, et al: Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 69: 8009-8016, 2009.
69. Kataoka Y, Mukohara T, Tomioka H, et al: Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs 30: 1352-1360, 2012.
70. Shah MA, Wainberg ZA, Catenacci DV, et al: Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 8: e54014, 2013.
71. Freidlin B, McShane LM, Polley MY and Korn EL: Randomized phase II trial designs with biomarkers. J Clin Oncol 30: 3304-3309, 2012.
72. Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10: 2298-2308, 2011.
73. Schoffski P, Sgroi M, Burris HA, Lutzky J, Rearden T, Sikic B, et al: Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. EJC Supplements 8: 117, 2010.
74. Kim MJ, Nam HJ, Kim HP, et al: OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 335: 145-152, 2013.
75. Oh D, Han S, Kim TM, et al: A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors. J Clin Oncol 28: e13056, 2010.
76. Camacho LH, Moulder SL, LoRusso PM, et al: First in human phase I study of MK-2461, a small molecule inhibitor of cMET, for patients with advanced solid tumors. J Clin Oncol 26 (Suppl 15): abs. 14657, 2008.
77. Falchook GS, Fu S, Amin HM, Piha-Paul SA, Hong DS, Naing A, et al: 1245 Poster Phase I dose-escalation study of the oral selective C-Met inhibitor EMD 1204831 in patients with advanced solid tumours. Eur J Cancer 47: S158, 2011.
78. Buchanan SG, Hendle J, Lee PS, et al: SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 8: 3181-3190, 2009.
79. Awazu Y, Nakamura K, Mizutani A, et al: A Novel Inhibitor of cMET and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities. Mol Cancer Ther 12: 913-924, 2013.
80. Oh YM, Song YJ, Lee SB, et al: A new anti-cMET antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol Cells 34: 523-529, 2012.
81. Nakagawa T, Tohyama O, Yamaguchi A, et al: E7050: a dual cMET and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 101: 210-215, 2010.
82. Goetsch L, Gonzalez A, Geronimi F, Fabre-Lafay S, et al: Single or combined in vivo therapies of cancer with h224G11, a humanized antibody targeting the cMET receptor. Mol Cancer Ther 8: B127, 2009.
83. Corso S, Ghiso E, Cepero V, et al: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 9: 121, 2010.
84. Qi J, McTigue MA, Rogers A, et al: Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71: 1081-1091, 2011.
85. Lee NV, Lira ME, Pavlicek A, et al: A novel SND1-BRAF fusion confers resistance to cMET inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS One 7: e39653, 2012.
86. Cepero V, Sierra JR, Corso S, et al: MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 70: 7580-7590, 2010.
87. Marangoni E, Vincent-Salomon A, Auger N, et al: A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998, 2007.
88. Amemiya H, Kono K, Mori Y, et al: High frequency of cMET expression in gastric cancers producing alpha-fetoprotein. Oncology 59: 145-151, 2000.